Using Etomoxir to Inhibit Fatty Acid Oxidation

Selective only in a narrow range, and routinely used far above it.

Mechanism and Range

Etomoxir is converted intracellularly to etomoxiryl-CoA, which inhibits CPT1A at the catalytic site. The inhibition is irreversible in practice, so pre-incubation matters, and the effect persists after washout to the extent that new enzyme is needed.

ConcentrationSelectivityObservation
1–3 µMLargely CPT1AModest FAO inhibition in many cells; requires sensitive flux measurement
5–20 µMPartial off-targetAdenine nucleotide translocator and complex I effects reported
50–200 µMBroadCoA homeostasis disrupted; proliferation inhibited independently of FAO
Above 200 µMCytotoxicNot interpretable as CPT1A inhibition

Caveat on the literature values. The most-cited concentrations in cancer metabolism papers are 100–200 µM, which is in the broad-effect range. A phenotype at that concentration is a phenotype of etomoxir, not necessarily of CPT1A. This is not a minor technicality: it has produced a decade of conflicting conclusions about whether fatty acid oxidation is required for proliferation.

Part 1 — What the Off-Target Effects Are

TargetEffectConsequence
Adenine nucleotide translocatorReduced ADP/ATP exchangeRespiration falls without a change in substrate supply
Complex IInhibition at higher concentrationsOxygen consumption falls for a non-FAO reason
Coenzyme A poolDepletion of free CoABroad metabolic disruption, including glucose oxidation
Carnitine shuttleIndirectOverlaps with the intended effect

Important distinction. All four of these reduce oxygen consumption, which is why an OCR-based readout cannot distinguish CPT1A inhibition from the off-target effects. The discriminating measurement is substrate-specific: palmitoyl-carnitine-driven respiration in permeabilised cells, where the substrate bypasses CPT1A and the off-target effects are visible as a change in the palmitoyl-carnitine-independent baseline.

Part 2 — Design

ParameterRecommendationWhy
Pre-incubation30–60 minutes before the fatty acid challengeIrreversible inhibition requires time to accumulate
Concentration series1, 3, 10, 30 µMEstablishes where the effect saturates and where off-target appears
VehicleDMSO or ethanol matchedBoth solvents affect respiration at higher volumes
Positive controlA genetic CPT1A knockdown, or octanoateRoute specificity
ReadoutAcyl-carnitine profile plus a flux measurementTogether they distinguish entry from downstream effects
ViabilityAt the assay timepointSeparates metabolic from cytotoxic effects

The fourth row is the one that converts the experiment from suggestive to interpretable. Octanoate enters mitochondria without CPT1A, so if etomoxir blocks palmitate oxidation but not octanoate oxidation, the effect is at the entry step. That comparison is cheap and decisive.

Part 3 — Alternative and Complementary Tools

ToolMechanismBest use
CPT1A knockdown or knockoutGeneticSpecificity; slower
Inducible CPT1A knockdownGenetic, titratableAvoids clonal adaptation
RanolazinePartial CPT1 inhibitionClinical context; partial effect
PerhexilineCPT1 and CPT2 inhibitionCardiac models; narrow therapeutic window
Malonyl-CoA elevation (ACC activation)Physiological inhibitionTests the endogenous gate
Substrate restriction (low fatty acid medium)Removes substrateTests dependence without inhibiting the enzyme

Readout note. Substrate restriction is the cleanest way to test whether a phenotype depends on fatty acid oxidation, because it removes the substrate rather than inhibiting a protein. In medium with delipidated serum and no added fatty acids, oxidation is low; the phenotype that disappears under those conditions is FAO-dependent by definition. The limitation is that serum delipidation removes other lipids as well, so the comparison should include a lipid add-back arm.

Part 4 — Interpreting Partial Effects

Etomoxir rarely abolishes fatty acid oxidation completely. A partial reduction is the expected result at selective concentrations and should be reported as such.

  • • A 30–50% reduction at 1–3 µM is consistent with partial CPT1A inhibition and is adequate to test dependence if the phenotype follows the flux.
  • • A near-complete reduction at high concentration is more likely to reflect off-target effects than complete enzyme inhibition.
  • • A phenotype without a flux change indicates that the effect is not mediated by oxidation, whatever the concentration.

The third pattern is common and is usually reported as "FAO inhibition prevented the phenotype", which inverts the logic: if flux did not change, the phenotype cannot be attributed to flux.

Part 5 — Common Failures

  • • 100–200 µM used as "CPT1A inhibition".
  • • No pre-incubation, so the irreversible inhibition has not developed.
  • • OCR used as the only readout, which cannot separate the targets.
  • • No genetic or substrate-bypass control.
  • • Acyl-carnitine profile not measured, discarding the diagnostic of where the block is.
  • • Partial inhibition reported as complete.
  • • A phenotype without a flux change attributed to FAO.
  • • Vehicle effects unmeasured at the volumes used for high concentrations.

Part 6 — Where This Article Connects

This is the protocol companion to the fatty acid oxidation article, which covers the flux measurements and the conditional direction of the effect. The palmitate delivery article determines the substrate load that etomoxir is acting against; the triglyceride assay measures where the unoxidised acyl-CoA went.

If you need FAO dependence tested with a concentration series and a substrate-bypass control, we can scope the design with you.

Contact EDITGENE to request a project consultation or quote.

Scientific scope and validation note

Selectivity, potency and off-target profile vary by cell type, concentration and exposure time; the ranges here are indicative and require local verification.

Inhibition of fatty acid oxidation does not establish that oxidation is required for a phenotype, unless flux and dependence are measured separately.

Scientific interpretation and experimental design

  • • Selective only at low micromolar. Above that, it is a different experiment.
  • • Pre-incubate. Irreversible inhibition takes time.
  • • Octanoate is the bypass control.
  • • Acylcarnitines locate the block.
  • • Partial inhibition is the expected result. Report it as such.
  • • Flux first, phenotype second. Otherwise the attribution fails.

Selected references for further reading

  • • Yao CH, et al. Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of β-oxidation. PLOS Biology. 2018;16:e2003782.
  • • Ceccarelli SM, et al. Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective. Journal of Medicinal Chemistry. 2011;54:3109–3152.
  • • McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. European Journal of Biochemistry. 1997;244:1–14.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: